RT Journal Article
SR Electronic
T1 Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 872
OP 878
DO 10.1136/annrheumdis-2018-214280
VO 78
IS 7
A1 Kevin L Winthrop
A1 Michael E Weinblatt
A1 Mary K Crow
A1 Gerd R Burmester
A1 Philip J Mease
A1 Alexander K So
A1 Vivian Bykerk
A1 Ronald F Van Vollenhoven
A1 Maxime Dougados
A1 Jonathan Kay
A1 Xavier Mariette
A1 Joachim Sieper
A1 Fritz Melchers
A1 Bruce N Cronstein
A1 Ethan Shevach
A1 Ferdinand C Breedfeld
A1 Joachim Kalden
A1 Josef S Smolen
A1 Daniel E Furst
YR 2019
UL http://ard.bmj.com/content/78/7/872.abstract
AB To develop a comprehensive listing of the greatest unmet scientific and clinical needs in rheumatology. The 20th annual international Targeted Therapies meeting brought more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of five disease-specific groups with 20–30 experts assigned to each group based on expertise. Specific groups included rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, connective tissue diseases and a basic science immunology group spanning all of these clinical domains. In each group, experts were asked to consider recent accomplishments within their clinical domain in the last year and update the unmet needs in three categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. While progress was noted among some of previously identified needs, both new needs were identified and themes from prior meetings were re-iterated: the need for better understanding the heterogeneity within each disease, and for identifying preclinical states of disease allowing treatment and prevention of disease in those at risk, and the elusive ability to cure disease. Within the clinical care realm, improved comorbidity management and patient-centred care continue to be unmet needs, and the need for new and affordable therapeutics was highlighted. Unmet needs for new and accessible targeted therapies, disease prevention and ultimately cure remain a priority in rheumatology.